

RESEARCH ARTICLE

Novel phenotype of *Wolbachia* strain *wPip* in *Aedes aegypti* challenges assumptions on mechanisms of *Wolbachia*-mediated dengue virus inhibition

Johanna E. Fraser^{1*}, Tanya B. O'Donnell¹, Johanna M. Duyvestyn¹, Scott L. O'Neill¹, Cameron P. Simmons^{1,2,3}, Heather A. Flores¹

1 World Mosquito Program, Institute of Vector-Borne Disease, Monash University, Clayton, Australia, **2** Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam, **3** Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

* Johanna.Fraser@monash.edu



OPEN ACCESS

Citation: Fraser JE, O'Donnell TB, Duyvestyn JM, O'Neill SL, Simmons CP, Flores HA (2020) Novel phenotype of *Wolbachia* strain *wPip* in *Aedes aegypti* challenges assumptions on mechanisms of *Wolbachia*-mediated dengue virus inhibition. *PLoS Pathog* 16(7): e1008410. <https://doi.org/10.1371/journal.ppat.1008410>

Editor: Jesus G. Valenzuela, National Institute of Allergy and Infectious Diseases, UNITED STATES

Received: February 13, 2020

Accepted: May 29, 2020

Published: July 29, 2020

Copyright: © 2020 Fraser et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files.

Funding: This work was supported by Wellcome Trust award No.102591/Z/13/Z (CPS and SON), and National Health and Medical Research Council Australia Ideas Grant APP1182432 (JEF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Abstract

The bacterial endosymbiont *Wolbachia* is a biocontrol tool that inhibits the ability of the *Aedes aegypti* mosquito to transmit positive-sense RNA viruses such as dengue and Zika. Growing evidence indicates that when *Wolbachia* strains *wMel* or *wAlbB* are introduced into local mosquito populations, human dengue incidence is reduced. Despite the success of this novel intervention, we still do not fully understand how *Wolbachia* protects mosquitoes from viral infection. Here, we demonstrate that the *Wolbachia* strain *wPip* does not inhibit virus infection in *Ae. aegypti*. We have leveraged this novel finding, and a panel of *Ae. aegypti* lines carrying virus-inhibitory (*wMel* and *wAlbB*) and non-inhibitory (*wPip*) strains in a common genetic background, to rigorously test a number of hypotheses about the mechanism of *Wolbachia*-mediated virus inhibition. We demonstrate that, contrary to previous suggestions, there is no association between a strain's ability to inhibit dengue infection in the mosquito and either its typical density in the midgut or salivary glands, or the degree to which it elevates innate immune response pathways in the mosquito. These findings, and the experimental platform provided by this panel of genetically comparable mosquito lines, clear the way for future investigations to define how *Wolbachia* prevents *Ae. aegypti* from transmitting viruses.

Author summary

Dengue virus, transmitted by the *Aedes aegypti* mosquito, is one of the fastest-growing infectious diseases, causing an estimated 390 million human infections per year worldwide. Vaccines have limited efficacy and there are no approved therapeutics. This has driven the rise of novel vector control programs, in particular those that use the bacterium, *Wolbachia*, which prevents transmission of dengue and other human pathogenic viruses when stably introduced into *Ae. aegypti* populations. Although this is proving to

Competing interests: The authors have declared that no competing interests exist.

be a highly effective method, the details of how this biocontrol tool works are not well understood. Here we characterise a new *Wolbachia* strain, wPip, and find that *Ae. aegypti* carrying wPip are still able to transmit dengue similar to mosquitoes that do not carry *Wolbachia*. This finding has allowed us to begin a rigorous program of comparative studies to determine which features of a *Wolbachia* strain determine whether it is antiviral. Understanding these mechanisms will enable us to predict the risk of viral resistance arising against *Wolbachia* and facilitate preparation of second-generation field release lines.

Introduction

The *Aedes aegypti* mosquito is the primary vector for many human pathogenic viruses including dengue (DENV), Zika (ZIKV) and chikungunya (CHIKV). Global incidence of arthropod-borne viruses (arboviruses) such as these is increasing in response to urbanization in the tropics, as well as globalization and expansion of the geographical range of *Ae. aegypti* [1, 2]. Arboviruses like DENV are typically associated with acute, self-limiting febrile disease, although severe manifestations can occur, in some instances leading to death. There are currently no approved specific antiviral therapeutics for DENV, ZIKV or CHIKV and recently developed vaccines for DENV are suboptimal and controversial [3–6]. As such, treatment is supportive only and limiting virus transmission is largely dependent on vector control. Conventional vector control programs attempt to suppress mosquito populations by removing breeding sites, or using insecticide sprays targeting adult mosquito habitats. However, the increasing incidence of these diseases demonstrates that current control programs are failing and there is a need for novel efficacious and cost-effective alternatives.

A new generation of vector control approaches exploits the obligate endosymbiont, *Wolbachia pipientis*. Various strains of *Wolbachia* are naturally found in at least 40% of insect species [7]. *Wolbachia* is maternally transmitted, and some strains induce a phenomenon known as cytoplasmic incompatibility (CI) which provides a reproductive advantage to females that carry *Wolbachia*. Significantly, many *Wolbachia* strains can protect arthropod hosts from viral infection [8–11]. *Wolbachia* is not typically found in *Ae. aegypti*, but it can be stably transferred into these mosquitoes by microinjection. Some *Wolbachia* strains including wMel (derived from *Drosophila melanogaster*) and wAlbB (from *Ae. albopictus*), protect *Ae. aegypti* from infection by flaviviruses such as DENV and ZIKV, and alphaviruses including CHIKV [12–15]. Recent field trials have tested the utility of these mosquitoes as a biocontrol method. Aided by maternal transmission, as well as CI, short term releases of wMel- or wAlbB-carrying *Ae. aegypti* have resulted in rapid introgression into wild *Ae. aegypti* populations. Recent reports indicate this can significantly reduce DENV incidence [16–18].

Despite success of these field trials, we do not understand how *Wolbachia* inhibits arbovirus infection. Several hypotheses have been proposed, including competition between *Wolbachia* and viruses for metabolic resources and physical space within host cells [11, 19–21], modification of host gene expression, and immune priming in new hosts [11, 22–24]. Specifically, multiple studies have shown that *Wolbachia* induces changes in cellular cholesterol and lipid homeostasis [25–27], and DENV replication can in part be restored in *Wolbachia*-carrying *Ae. aegypti* cells or mosquitoes by chemical modulation of cholesterol content, or diet supplementation [25, 27]. Recent work has also shown that changes in host gene expression due to the presence of *Wolbachia* may be an important driver of the antiviral state, with the mosquito insulin receptor [28], and cadherin [29] identified as key targets.

Table 1. *Wolbachia* stains that have been introduced into *Ae. aegypti* to date.

Host species	<i>Wolbachia</i> strain(s)	<i>Wolbachia</i> supergroup	References
<i>D. melanogaster</i>	wMel, wMelCs, wMelPop	A	[15, 32–34]
<i>D. simulans</i>	wRi, wAu	A	[32, 34]
<i>Ae. albopictus</i>	wAlbA, wAlbB	A and B, respectively	[34–37]
<i>Cx. quinquefasciatus</i>	wPip	B	[32]

<https://doi.org/10.1371/journal.ppat.1008410.t001>

Despite this information, how these effects are induced, and why they impact DENV, is largely unclear. Understanding the contributions of each of these mechanisms to arboviral inhibition in *Wolbachia*-carrying *Ae. aegypti* has proven to be complex, and it is likely that the antiviral syndrome that *Wolbachia* species induce in the host is multi-layered, with no single mechanism responsible for this phenotype [30, 31].

We and others have produced and characterized a series of *Ae. aegypti* lines transfected with different *Wolbachia* strains (summarized in Table 1), including several strains from *Drosophila* species, and different mosquito species.

So far, all 7 of the *Wolbachia*-carrying *Ae. aegypti* lines tested have provided some level of protection against flaviviruses. Here, we characterize the vector competence of *Ae. aegypti* transfected with wPip (from *Culex quinquefasciatus*, supergroup B). Past data has suggested that removal of wPip from its natural host by antibiotic treatment leads to an increase in the replication of DENV-related flavivirus West Nile virus (WNV), indicating that wPip may be antiviral in this context [38]. We previously reported the generation of a wPip-*Ae. aegypti* line [32], and that wPip resides at a high density in *Ae. aegypti*—a feature widely regarded as important for *Wolbachia* to impart its antiviral effects [39–41]. However, we show here that wPip does not restrict flavivirus replication or dissemination, and these mosquitoes transmit infectious virus. We leverage this finding to understand more about what makes a *Wolbachia* strain antiviral. We compare the density and tissue specificity of wPip and antiviral strains wMel and wAlbB, in *Ae. aegypti* backcrossed onto the common laboratory Rockefeller *Ae. aegypti* line and identify no link between strains that reside at high density in the midgut or salivary glands, and those that protect against DENV. Furthermore, we determine that commonly used proxies of immune activation of the host are not induced by all antiviral *Wolbachia* strains. Thus, our finding of a *Wolbachia* strain that does not inhibit DENV replication in *Ae. aegypti* has allowed us to isolate the antiviral effects of *Wolbachia* from the general symbiont effects for the first time in this mosquito species, enabling us to resolve conflicting reports regarding the mechanisms that drive *Wolbachia*-mediated virus inhibition.

Results

wPip does not block flavivirus replication in virus-injected *Ae. aegypti*

Past reports suggest wPip is a good antiviral candidate for testing in *Ae. aegypti*, as it may provide viral protection to *Cx. quinquefasciatus* [38], and it resides at high density in *Ae. aegypti* [32]. We assessed the vector competence of wPip-*Ae. aegypti* by intrathoracic injection challenge and infectious blood meal, comparing DENV replication in this line to a matched *Wolbachia*-free line (tetracycline-treated wPip-*Ae. aegypti*; wPip.Tet). As a control, we included wMel-*Ae. aegypti* (predominantly used by the World Mosquito Program as their field release line), and its matched *Wolbachia*-free line (wMel.Tet).

Briefly, 60 seven-day old females were injected with 6.3×10^5 TCID₅₀/ml of DENV-3, or a 10-fold dilution thereof. Total RNA was extracted from whole, surviving mosquitoes 7 days post infection. Absolute DENV-3 RNA copies were determined in each mosquito by qRT-PCR and




Fig 1. wPip does not inhibit flavivirus replication in virus-injected *Ae. aegypti*. Intrathoracic injections of 6 or 7-day old female mosquitoes were performed: (A) DENV-3 at 6.3×10^5 TCID₅₀/ml or (B) 6.3×10^4 TCID₅₀/ml, and (C) KUNV at 1.4×10^7 TCID₅₀/ml or (D) 1.4×10^6 TCID₅₀/ml. RNA was extracted from whole mosquito bodies 7-days post infection and virus replication was quantified by qRT-PCR. Data are the mean number of virus genome copies per mosquito (DENV) or per *RPS17* mosquito house-keeping gene (KUNV) \pm SEM with individual data points overlaid. Data are representative of 2 independent experiments. Number of DENV-3/KUNV positive mosquitoes/total injected mosquitoes are indicated above each bar. Statistical analyses were performed using a Mann-Whitney test where * $p < 0.05$, *** $p < 0.001$, **** $p < 0.0001$.

<https://doi.org/10.1371/journal.ppat.1008410.g001>

extrapolation to a standard curve. Consistent with previous reports, wMel restricted DENV replication by approximately $1 \log_{10}$ compared to its matched Tet control line, when injected with either concentration of virus (Fig 1A and 1B) [32, 42]. Notably, 37 of 49 injected wMel mosquitoes scored positive for DENV-3 infection (>1000 copies/mosquito, based on the Limit of Detection 95%) when injected with 6.3×10^5 TCID₅₀/ml, compared to just 15 of 47 wMel mosquitoes when injected with 6.3×10^4 TCID₅₀/ml (Fig 1A and 1B, in parenthesis above the bar charts),

consistent with better viral restriction occurring when the mosquitoes are challenged with a lower virus titre [32]. In stark contrast to the protection afforded by wMel, wPip did not inhibit either concentration of DENV-3 compared to the matched wPip.Tet control line. As well as failing to reduce the amount of virus in these mosquitoes, the number of infected wPip-mosquitoes also remained high and comparable to the matched wPip.Tet control line, demonstrating this *Wolbachia* strain does not provide antiviral protection when transinfected into *Ae. aegypti*.

Since wPip may inhibit WNV in its native host mosquito species, *Cx. quinquefasciatus* [38], we next examined whether wPip could inhibit WNV in an *Ae. aegypti* host. *Ae. aegypti* carrying wPip, wMel, or their respective Tet control lines, were injected with WNV strain Kunjin virus (KUNV) at 1.4×10^7 TCID₅₀/ml or a 10-fold dilution thereof. Mosquitoes were collected 7-days post-infection and RNA was isolated from whole mosquitoes. Total KUNV RNA copies relative to mosquito host *RPS17* RNA, was determined in each mosquito by qRT-PCR. Similar to previous reports, wMel provided substantial protection against KUNV, with 2 or 5log₁₀ reductions in viral RNA copies measured in wMel-infected mosquitoes compared to wMel.Tet when injected with high and low virus concentrations, respectively (Fig 1C and 1D) [42]. However, as was observed for DENV-3 infections, wPip failed to provide protection against KUNV at either high or low concentrations of virus. Thus, wPip is not antiviral towards multiple flaviviruses in *Ae. aegypti*.

wPip does not restrict DENV replication, dissemination or transmission in *Ae. aegypti* following an infectious blood meal

Since the route of viral infection can affect the ability of a *Wolbachia* strain to inhibit flaviviruses [35], we next examined the impact of wPip on *Ae. aegypti* infection by DENV following an infectious blood meal. Female mosquitoes carrying wMel or wPip and their respective Tet control lines were fed a blood meal containing freshly harvested cell culture-derived DENV-3 (6.6×10^6 TCID₅₀/mL diluted 1:1 in sheep blood). Mosquitoes were incubated for 15 days, then the body and head of the mosquito were collected separately as indicators of established infection and viral dissemination, respectively. No wMel-carrying mosquitoes that took a blood meal established a DENV-3 infection, compared to 71% of the matched Tet control cohort, and a $>4\log_{10}$ reduction in mean DENV-3 copies/body were observed in the presence of wMel (Fig 2A Bodies and Table 2). By contrast, 89% of wPip-transinfected mosquito bodies scored positive for DENV-3, similar to 97% of the matched Tet control cohort, with a slight, although significant, increase in the mean viral copies/body in wPip-carrying mosquitoes compared to its matched Tet control cohort. No wMel mosquitoes had viral RNA disseminated to their heads, compared to 72% of wMel.Tet mosquitoes (Fig 2A Heads and Table 2). Similar numbers of wPip- and wPip.Tet-carrying mosquitoes scored positive for disseminated infection (83% and 96%, respectively), and the mean DENV copies/head was slightly but significantly reduced in wPip-infected mosquitoes compared to wPip.Tet. Note that the slight increases and decreases in viral copy number observed for wPip-carrying mosquitoes compared to the Tet control line are likely to be due to biological variability, as they were not consistent across 3 independent experiments (S1 Fig). The overall trend clearly showed no difference between the vector competence of these two lines.

We further examined the saliva from a proportion of mosquitoes that were fed a virus-spiked blood meal to determine whether infectious virus could be transmitted by wPip-carrying mosquitoes. Saliva was collected from ~15 mosquitoes/line (donor mosquitoes) at 14-days post-infection. Each saliva sample was then injected into the thorax of 6 wMel.Tet recipient mosquitoes to assess the replication competence of the virus in a common host. Seven days later, injected mosquitoes were harvested, total RNA was extracted and qRT-PCR performed

Table 2. Restriction of DENV-3 infection and dissemination by wPip.

	Body	Head	Saliva
Line	% DENV + [#] (<i>n</i> = 87)	% DENV + [#] (<i>n</i> = 87)	Donor mosquitoes with infectious saliva (<i>n</i>)
wMel	0	0	0 (15)
wMel.Tet	71	72	6 (14)
wPip	89	83	3 (14)
wPip.Tet	97	96	5 (13)

[#] Calculated as a percentage of total engorged mosquitoes.

(*n*) total mosquitoes examined.

<https://doi.org/10.1371/journal.ppat.1008410.t002>

to determine the number of recipients positive for virus infection ($>10^3$ DENV copies/mosquito). wMel caused a significant reduction in the number of donor mosquitoes that carried infectious DENV in their saliva, compared to its matched Tet control line (Fisher's exact test $p < 0.05$), but wPip did not (Fig 2B and Table 2).

These data consistently demonstrate that wPip does not provide *Ae. aegypti* mosquitoes with protection against DENV-3 infection or dissemination, and infectious virus is produced by mosquitoes that carry wPip.

Differences in mosquito host genetics do not underlie wPip's lack of antiviral activity

Following microinjection of a new *Wolbachia* strain into *Ae. aegypti*, an intense genetic bottlenecking occurs as we select individual mosquitoes that carry *Wolbachia*. To determine whether the lack of antiviral activity observed for wPip was due to specific genetic features of the host mosquito selected during this process, we backcrossed our *Wolbachia*-carrying lines to the inbred laboratory mosquito line, Rockefeller, through six generations, placing each *Wolbachia* strain into the same nuclear genetic background. Intrathoracic injection of these lines with DENV-2 confirmed a lack of viral restriction by wPip (S2 Fig). Thus, the inability of wPip-*Ae. aegypti* to inhibit flaviviruses is consistent in different *Ae. aegypti* nuclear backgrounds.

High *Wolbachia* density in *Ae. aegypti* salivary glands and midgut is not required for viral inhibition

Our novel identification of a *Wolbachia* strain that does not appear to restrict flaviviruses in *Ae. aegypti*, generated an opportunity to determine what features of *Wolbachia* are common to antiviral strains. Several reports have suggested that the ability of a *Wolbachia* strain to inhibit viruses is dependent on the density at which it resides in its host [39–41]. Our previous work demonstrated that wPip resides at similar or slightly higher levels than wMel in whole *Ae. aegypti* mosquitoes throughout the adult lifespan [32]. However, it is not known whether these strains reside differentially within specific tissues that may explain the disparity in their antiviral activity. To test this rigorously we used our Rockefeller *Ae. aegypti* lines carrying the antiviral *Wolbachia* strains wMel or wAlbB (classified as *Wolbachia* supergroup A and B strains, respectively), or wPip (from supergroup B), to compare the densities of *Wolbachia* in the salivary glands and midguts of female mosquitoes/line, 6–7 days post emergence. *Wolbachia* density was determined by amplifying the conserved *Wolbachia* 16S rRNA gene and normalising this to the *Ae. aegypti* host RPS17 gene. All 3 *Wolbachia* strains were found to reside at similar densities in whole mosquitoes (between 10 and 14 *Wolbachia* per host cell, Fig 3A). Although




Fig 3. High *Wolbachia* density in *Ae. aegypti* salivary glands and midgut is not required for viral inhibition. (A-F) Density of *Wolbachia* within female mosquitoes was determined by qPCR following DNA extraction from whole mosquitoes, or from dissected tissues including salivary glands, head/thorax, midgut, abdomen (ovaries removed), or ovaries, as indicated (6–7 days post-emergence). Density is expressed as the mean ratio between the conserved *Wolbachia* 16S rRNA gene and the *Ae. aegypti* host RPS17 gene. Data are the mean and SEM of 24 mosquitoes.

Asterisks indicate significance compared to *Ae. aegypti*-wMel (Kruskal-Wallis test with Dunn's correction; ** $p < 0.01$, *** $p < 0.0001$). G) Salivary glands were dissected from 6 female mosquitoes 6 days post emergence and stained by fluorescence *in situ* hybridization (FISH) using probes that detect the conserved *Wolbachia* 16S rRNA gene and DAPI to demarcate the salivary gland tissue. Slides were imaged as 3-dimensional z-stacks and 2D images generated by Maximum Intensity Projection (MIP) using Fiji software. Images are representative of >8 salivary gland sets per mosquito line, from 2 independent experiments. Scale bar: 100 μm .

<https://doi.org/10.1371/journal.ppat.1008410.g003>

mosquito salivary glands must become infected with virus in order for the mosquito to transmit DENV, we do not know whether this tissue contributes to virus inhibition by supporting high levels of *Wolbachia*. We tested whether antiviral *Wolbachia* strains localise in this tissue at a higher density than the non-inhibitory strain, wPip. Surprisingly, the mean relative wMel density was shown to be very low (1 *Wolbachia* per host cell), while wAlbB and wPip resided at substantially and significantly higher mean levels (11 and 13 *Wolbachia* per host cell; $p < 0.0001$ Kruskal-Wallis test) (Fig 3B). Given this unexpected finding, we next examined whether the tissues surrounding the salivary glands may be contributing high *Wolbachia* densities to mediate the antiviral phenotype observed for wMel-carrying mosquitoes. To do this we separated the head/thorax from the abdomen of mosquitoes and determined the *Wolbachia* density. The densities of wMel, wAlbB and wPip in the head/thorax closely reflected what was observed in salivary glands alone (Fig 3C). It therefore appears that high levels of *Wolbachia* are not required in or around the salivary glands in order to provide an antiviral phenotype. Similarly, the findings for wPip demonstrate that high levels of *Wolbachia* can reside in this critical tissue and not impact virus inhibition.

We next used confocal laser scanning microscopy to examine whether wPip localises differently within the salivary gland tissue, to enable DENV replication. Salivary glands were dissected from female mosquitoes 6 days post emergence and stained by fluorescence *in situ* hybridization (FISH) using probes that detect the conserved *Wolbachia* 16S rRNA gene [11] and DAPI to demarcate the salivary gland tissue. Slides were imaged as 3D z-stacks and 2D images were generated by Maximum Intensity Projection (MIP) using Fiji software. As expected, there was negligible staining observed in the Rockefeller control samples indicating the specificity of the FISH probes (Fig 3G). wPip localized similarly to the antiviral strain wAlbB, at high levels, but quite diffusely throughout the three lobes of the salivary glands. Consistent with the lower levels of wMel measured by qPCR, this *Wolbachia* strain appeared less prevalent, although interestingly, it was observed to localize in one clustered location of a single lobe. Together, these results show that antiviral *Wolbachia* strains can localise differently within the salivary glands, and that high levels of *Wolbachia* are not required in this tissue to prevent DENV transmission. Therefore, it is more likely that the antiviral effects of wMel and perhaps wAlbB are initiated at tissues that are infected earlier, rather than at disseminated sites such as the salivary glands.

We next examined the density of these *Wolbachia* strains in the midgut of the mosquito (the site of virus adsorption and internalization following an infectious blood meal). Interestingly, wMel was present at very low mean levels in the midgut (0.1 *Wolbachia* per host cell; Fig 3D). wPip mean levels were approximately 6 times higher than wMel (0.6 *Wolbachia* per host cell), while wAlbB resided at the highest density (mean 2.5 *Wolbachia* per host cell; Fig 3A).

To examine whether tissues surrounding the midgut contain high levels of wMel that may explain limited DENV replication in the body of these mosquitoes, we measured the density of each *Wolbachia* strain in mosquito abdomens. Ovaries were removed from the dissected abdomens prior to DNA extraction to prevent obscuring by the high levels of wMel in this tissue. While the *Wolbachia* densities were substantially higher for all lines compared to the midgut alone, the trend across the three lines was almost identical with wMel residing at the lowest

density, then wPip, with wAlbB residing at the highest density (Fig 3E). Thus, the tissues immediately surrounding the midgut are not supporting high levels of wMel to supplement the lower *Wolbachia* densities observed in this tissue.

Analyses of ovaries dissected from each line identified that the high density of wMel observed in whole mosquitoes was largely driven by ovary-localization (Fig 3F). wMel was present in ovaries at 48 *Wolbachia* per host cell, significantly higher than in the ovaries of wAlbB- and wPip-carrying mosquitoes (9 and 13 *Wolbachia* per cell, respectively; $p < 0.0001$ Kruskal-Wallis test). Interestingly, previously reported maternal transmission rates for *Wolbachia* strains wMel, wAlbB and wPip in *Ae. aegypti* are almost always 100% [15, 32, 36] suggesting that the significantly lower levels of wAlbB and wPip in the ovaries are sufficient to support a high rate of maternal transmission.

Of note, wAlbB and wPip (both belonging to supergroup B and therefore more closely related to each other than to wMel) seem to display similar tissue distribution and densities in all the tissues examined here, while the profile of wMel is quite different. These findings indicate that a strict localization and density profile at the tissue level is not linked to the antiviral phenotype of *Wolbachia* strains.

Wolbachia*-mediated antiviral protection is not dependent on elevated innate immune response pathways in *Ae. aegypti

We next tested the hypothesis that *Wolbachia* infection in *Ae. aegypti* elevates expression of several innate immune pathway components, particularly in novel *Wolbachia*-host associations, to create an antiviral environment [11, 22–24]. To do this we used our panel of genetically comparable Rockefeller *Ae. aegypti*-*Wolbachia* lines, with the addition of wMelPop (also in the Rockefeller background)—a strongly antiviral *Wolbachia* strain that enhances expression of innate immune pathway components in *Ae. aegypti* [11, 22–24]. We assessed the expression levels of Toll pathway components (*cecropin D*, *cecropin E*, *defensin C*), known to control anti-DENV defences in mosquitoes [43], and previously reported to be upregulated by some *Wolbachia* strains in *Ae. aegypti* [11, 22–24]. We also assessed expression levels of *C-type lectin* (immune recognition molecule) and *transferrin* (regulation of oxidative stress through iron sequestration), other proteins involved in innate immunity and previously reported to be upregulated by some *Wolbachia* strains in *Ae. aegypti* [11, 22, 24].

Twenty-four female mosquitoes carrying wMel, wAlbB, wPip, wMelPop, or Rockefeller (no *Wolbachia* control) were collected 5-days post-emergence. Expression levels of immune molecules were measured by qPCR, and quantified relative to the mosquito gene *RPS17*. Mosquitoes carrying wMelPop had significantly elevated levels of each of these representative pathway components compared to the Rockefeller control (Kruskal-Wallis test, Fig 4A–4E). The magnitude of expression increase, relative to the Rockefeller control mosquitoes, varied between the transcripts examined with the smallest increase observed for *C-type lectin* (10-fold increase; Fig 4D) and the largest observed for *defensin C* (~250-fold; Fig 4C). In contrast, only very small or no increase in expression of these components was observed in *Ae. aegypti* carrying wMel, wAlbB or wPip, relative to the Rockefeller control. wMel did significantly increase expression of *cecropin E* and *defensin C* (Fig 4B, C), but these increases were very small in comparison to wMelPop (6- and 2.5-fold increases in the presence of wMel, compared to 180- and 270-fold increases in the presence of wMelPop) and were not observed for the other antiviral strain, wAlbB. Interestingly, *C-type lectin*, while significantly increased by wMelPop, was significantly decreased by all other strains relative to the Rockefeller control (Fig 4D). This is the first time *Wolbachia*-induced immune gene expression has been examined in genetically comparable *Ae. aegypti* lines, using a variety of *Wolbachia* strains that either inhibit or do not




Fig 4. Elevated innate immune response pathways are not required to mediate viral inhibition. (A-E) Expression levels of selected genes from innate immune pathways were measured by qRT-PCR in 5-day old female mosquitoes, relative to the *Ae. aegypti* host *RPS17* gene. Data are the mean and SEM of 24 mosquitoes, representative of 2 independent experiments. Asterisks indicate significance compared to Rockefeller (no *Wolbachia* control) (Kruskal-Wallis test with Dunn's correction; * $p < 0.05$, **** $p < 0.0001$).

<https://doi.org/10.1371/journal.ppat.1008410.g004>

inhibit DENV. Using this approach, we can state that elevated expression of these immune components is not consistently associated with a *Wolbachia*-mediated antiviral phenotype in *Ae. aegypti*.

Discussion

Dissecting the molecular mechanisms that underpin the inhibition of human pathogenic viruses by various *Wolbachia* strains will facilitate the continued success and longevity of *Wolbachia*-based biocontrol programs. This will provide a means to screen for the possible emergence of viral resistance prior to detecting an increase in human disease in *Ae. aegypti*-*Wolbachia* established areas. In addition, it will allow us to identify second-generation *Wolbachia* strains that may restrict viruses using different mechanisms.

wPip is the first *Wolbachia* strain that has been introduced into *Ae. aegypti* without providing antiviral protection towards flaviviruses. A recent study from Ant *et al.*, 2018, introduced wAlbA from *Ae. albopictus* into *Ae. aegypti*. This line carried wAlbA at a high density yet did not restrict DENV or ZIKV following intrathoracic viral injection [35]. However, when vector competence was examined following an infectious blood meal (DENV or ZIKV), viral infection, dissemination and transmission rates were significantly reduced [35]. We have previously shown that intrathoracic injection challenges with high virus concentrations can overwhelm

Wolbachia-mediated inhibition [32]. This mode of infection may underestimate the ability of a *Wolbachia* strain to inhibit arboviruses unless injections are performed using a range of virus concentrations. These findings demonstrate the importance of rigorous assay design for vector competence analyses.

Our generation of a novel panel of genetically comparable *Ae. aegypti* lines carrying different *Wolbachia* strains, including one with a non-antiviral strain (*wPip*), has allowed us to begin rigorously testing a series of hypotheses of the mechanisms underlying viral restriction by *Wolbachia*. Until recently, it was widely accepted that inhibition of viruses in this context correlated with *Wolbachia* density. This dogma was based on a series of experiments using mosquito cell culture and *Drosophila* lines carrying a variety of *Wolbachia* strains, or titrations of a single *Wolbachia* strain by antibiotic treatment [39–41, 44]. However, here we demonstrate that antiviral phenotype is not dictated by the density at which it resides in either the whole body, salivary glands, the midgut or the tissues immediately surrounding these in the mosquito. This conclusion is supported by a recent publication from Flores *et al.* who determined that *wMel* inhibits DENV replication in mosquito abdomens better than *wAlbB*, despite *wAlbB* residing at higher density than *wMel* in the midgut and abdomen as shown here [37]. Furthermore, it is consistent with reports that *wAlbA* resides at substantially higher levels than *wAlbB* and *wMel* in the midgut and the salivary glands of *Ae. aegypti*, despite *wAlbA* showing a relatively limited ability to inhibit flaviviral and alphavirus replication [34, 35]. Amuzu and McGraw (2016), examined this in another way, determining that the relationship between DENV inhibition and *wMel* density within a single *Ae. aegypti* tissue sample is not linear [45]. This finding supports our conclusion that it is not simply the amount of *Wolbachia* present in a tissue that determines whether or not a *Wolbachia* strain is able to inhibit DENV. Studies into flavivirus infection in mosquitoes without *Wolbachia* indicate that tissues including the midgut, trachea and salivary glands evidently become infected following virus uptake and dissemination [46, 47]. Since we report relatively high levels of *wPip* (non-antiviral) in the abdomen and salivary glands, it will be interesting to characterise how DENV can infect tissues already occupied by *Wolbachia*.

If *Wolbachia* does not have to be present at high densities to impair viral replication e.g. in the midgut, then this also questions an existing hypothesis that *Wolbachia* impairs viral replication by competing for space within host cells [11, 20, 21]. Further work is needed to analyse the subcellular localisation of various *Wolbachia* strains to examine whether this may determine the antiviral activity of a strain.

Several studies have implied that *Wolbachia* may prime the host innate immune system, preventing arboviral establishment [11, 22–24]. The importance of the contribution of this mechanism has been clouded by the fact that expression levels of these pathway components seems to vary depending on how long the *Wolbachia* strain has resided in its host [22]. We selected a series of immune effectors previously shown to be upregulated by *wMelPop*, *wMel* or *wAlbB* in *Ae. aegypti*, relative to no-*Wolbachia* control lines. These included toll pathway components (*cecropin D, E*, and *defensin C*), *C-type lectin* (immune recognition molecule), and oxidative stress regulator *transferrin* [11, 22–24]. Using our panel of comparable *Wolbachia*-Rockefeller mosquito lines our findings definitively show that these pathways do not need to be primed at high levels by *Wolbachia* in order to restrict viral replication. While we have not exhaustively considered all innate immune pathways, this finding is consistent with observations from Rances *et al.*, 2012, who identified upregulation of many immune genes only occurred in *wMel*- and *wMelPop*-*Ae. aegypti* where the endosymbiont was a newly acquired infection, but not in the original *D. melanogaster* host where both these strains are antiviral [22]. It is possible these strains may use overlapping mechanisms to inhibit viruses, but these data indicate that immune priming may be particular to *wMelPop*. The induction of these

pathways by wMelPop is of such a magnitude that they could be easily measured at the whole mosquito level, but refining the experiment to investigate expression levels in individual tissues may reveal smaller increases in expression levels by other *Wolbachia* strains.

We initially produced the wPip-*Ae. aegypti* line based on work in the native *Culex* mosquito host that showed removal of wPip led to enhanced levels of WNV [38]. Given that wPip does not protect against multiple flaviviruses in *Ae. aegypti*, our results show that there is likely to be a specific *Wolbachia*-host interaction that determines whether a *Wolbachia* strain creates an antiviral state in its host. This host-dependent context has previously been seen for wAlbB: this strain does not provide clear protection against flaviviruses in its native *Ae. albopictus* host [13], but effectively inhibits flaviviruses in *Ae. aegypti* [13, 34, 42].

While we are the first to stably introduce wPip into *Ae. aegypti*, wPip was previously introduced into *Ae. albopictus*: as a single infection, as a double infection with wMel [48], and as a triple infection with the natural wAlbA/wAlbB *Wolbachia* strains [49]. These studies have shown that wPip alone in *Ae. albopictus* is not antiviral, while combining wPip with wMel (previously shown to have antiviral activity in *Ae. albopictus*) does inhibit arboviruses, and the addition of wPip to the natural wAlbA/wAlbB combination significantly reduces DENV and ZIKV replication. This complicated scenario may suggest that wPip modifies these hosts in different ways, such that effects in *Ae. albopictus* cannot strictly be extrapolated to *Ae. aegypti*. Although it should be noted that wPip has at least 5 genetically distinct groups and it is possible that these groups may differ in their antiviral activity [50].

We should also be open to the possibility that where a consistent antiviral phenotype is observed for one *Wolbachia* strain in different hosts, multiple mechanisms that are species-specific may contribute to the antiviral phenotype.

The importance of host context was recently shown in another way by Ford *et al.* (2019), who selected for wMel-*Ae. aegypti* that impart strong or weak antiviral effects towards DENV. The group showed that mosquitoes that were more antiviral expressed higher levels of the host gene cadherin [29]. It will be of interest in future studies to determine whether all antiviral *Wolbachia* strains induce specific changes in host gene expression in *Ae. aegypti*, that are not induced by wPip.

The issue of host context poses an interesting issue for selecting *Wolbachia* strains for novel *Ae. aegypti* lines—that is, how can we predict whether a new strain will induce an antiviral state? Notably, so far it seems that the magnitude of the antiviral effect of a *Wolbachia* strain measured in *Drosophila spp.* predicts how the strain will behave in *Ae. aegypti* (from the 5 strains examined) [10, 11, 15, 32, 34, 44, 51]. This has not been the case for mosquito-derived *Wolbachia* strains—wAlbA and wAlbB are not antiviral in their native host, but do provide protection in *Ae. aegypti*, while wPip is reported to be antiviral in *Cx. quinquefasciatus*, but not in *Ae. aegypti* [13, 35, 38]. Perhaps this is due to differences in the way these *Wolbachia* strains localise in each host. And/or, if multiple mechanisms contribute to viral inhibition, perhaps each host-*Wolbachia* combination has some or all of these mechanisms in play. The introduction of other novel *Wolbachia* strains into *Ae. aegypti* is required to determine if this trend holds.

In this study we have generated a unique and powerful tool: a panel of *Ae. aegypti* lines that differ only in the *Wolbachia* strain that they carry, including wPip-*Ae. aegypti* which does not restrict flavivirus replication or dissemination. This is an important finding as it identifies a refined negative control that isolates the antiviral effects of *Wolbachia* for studies trying to understand how *Wolbachia* affects its host. A *Wolbachia*-free control has been used in the past, but this control does not account for the many host effects *Wolbachia* can induce just by residing as an endosymbiont, that may not be responsible for creating an antiviral state [52, 53]. In this way, we have been able to re-examine two hypotheses of how *Wolbachia* inhibits

arboviruses, that have been subject to multiple conflicting reports—the importance of tissue-specific *Wolbachia* density in predicting the antiviral activity of a strain in *Ae. aegypti*, and the role of immune priming in inhibiting flaviviruses. The strength of this approach was recently shown by LePage *et al.* (2017) who compared the genomes of *Wolbachia* strains that do or do not induce CI to manipulate host reproduction, identifying the two genes responsible for inducing this phenotype [54]. We have now initiated a series of experiments to carefully dissect the mechanisms that drive *Wolbachia*-mediated viral inhibition.

Methods

Mosquito rearing

All *Ae. aegypti* mosquitoes were reared and maintained as described previously [32, 33, 55]. Briefly, adult mosquitoes were maintained at 26°C, 65% relative humidity (RH) and a 12 h light:dark cycle in a climate-controlled room. Mosquitoes were blood fed on the arms of human volunteers (Monash University human ethics permit CF11/0766-2011000387). The *Wolbachia*-infected wMel, wAlbB and wPip lines as well as matched Tet-control lines (*Wolbachia* infected lines that have been cured of their infection by tetracycline treatment) used in these experiments have been described previously [15, 32, 37, 56]. Tet-control lines were backcrossed to their matched *Wolbachia*-carrying lines for a minimum of three generations to homogenise their genetic backgrounds.

To generate a panel of genetically comparable *Wolbachia*-carrying *Ae. aegypti* lines, we backcrossed females from the wMel, wAlbB, wMelPop and wPip to males of the inbred laboratory *Ae. aegypti* line, Rockefeller [57] (BEI resources), for six generations.

To exclude any influence of mosquito age on our experiments, age-controlled adults emerging within a 24 h window were used.

Vector competence

DENV-3 Cairns 08/09 strain (Genbank accession number: JN406515.1) and DENV-2 strain (originally isolated from a patient in Vietnam in 2010) were prepared by inoculation of C6/36 cells with a multiplicity of infection (MOI) of 0.1 and collection of culture supernatant 6–7 days later. KUNV stocks (Genbank accession number: MRM61C) were prepared by inoculation of C6/36 cells with a multiplicity of infection (MOI) of 1 and collection of culture supernatant 48 hours later. Virus concentrations were determined by TCID₅₀ as previously described [58] using monoclonal antibody 4G2 [59].

For feeding experiments with DENV-3 (Cairns 08/09) infected blood, 100 seven-day old age-controlled female mosquitoes were placed in 500 mL plastic containers (five containers per *Wolbachia* line, three containers per Tet line), starved for up to 24 h and allowed to feed on a 50:50 mixture of defibrinated sheep blood and tissue culture supernatant containing freshly harvested 6.6×10^6 TCID₅₀/mL of DENV-3. Feeding was done through a piece of desalted porcine intestine stretched over a water-jacketed membrane feeding apparatus pre-heated to 37°C. Mosquitoes were left to feed in the dark for approximately 1–2 hours. Fully engorged mosquitoes were placed in 500 mL containers at a density of < 25/container, and incubated for 15 d at 26°C with 65% RH and a 12 h light/dark cycle.

For adult microinjections, 60 six- or seven-day old age-controlled female mosquitoes were anesthetized by CO₂. Mosquitoes were injected intrathoracically with 69 nL of DENV (DENV-3 Cairns 08/09 strain at 6.3×10^5 or 6.3×10^4 TCID₅₀/ml, or DENV-2 Vietnam strain at 2.4×10^5) in RPMI media (Life Technologies) using a pulled-glass capillary and a handheld microinjector (Nanoject II, Drummond Scientific). For KUNV injections, 69 nL of 1.4×10^7 or 1.4×10^6 TCID₅₀/ml was injected per mosquito using the same method as described for DENV-3.

Injected mosquitoes were incubated for 7 days (15 mosquitoes/cup) at 26°C with 65% RH and a 12 h light/dark cycle.

To quantify DENV-3 or KUNV genomic copies, total RNA was isolated from mosquitoes (entire mosquitoes for injection experiments, or head and bodies separately for blood-fed mosquitoes) using the RNeasy 96 QIAcube HT kit (Qiagen). DENV-3 RNA was amplified by qRT-PCR (LightCycler Multiplex RNA Virus Master, Roche), using primers to the conserved 3'UTR: Forward 5'-AAGGACTAGAGGTTAGAGGAGACCC; Reverse 5'-CGTTCGTGTCC TGGAATGATG; Probe 5'-HEX- AACAGCATATTGACGCTGGGAGAGACCAGA-BHQ1-3' [60]; absolute copies were determined by extrapolation from an internal standard curve generated from plasmid DNA encoding the conserved 3'UTR sequence. Mosquito extracts with ≥ 1000 copies of DENV per body were scored positive, based on the LOD₉₅ (limit of detection 95%) for DENV-3 with this primer set. KUNV RNA was amplified by using primers that span the 3' end of the conserved NS5 gene, and the 3'UTR: Forward 5'-AACCCAGTGGAGAAG TGGA; Reverse 5'-TCAGGCTGCCACACCAAAA; Probe 5'-HEX -CGATGTTCCATACTCT GGCAAACG -BHQ1-3' [61]. KUNV RNA copies were quantified relative to *Ae. aegypti* house-keeping gene *RPS17* using the delta CT method ($2^{\text{CT}}(\text{reference})/2^{\text{CT}}(\text{target})$). KUNV RNA copies with a CT of < 33 were scored positive for infection. Note that all surviving mosquitoes were processed for virus injection experiments, while a maximum of 87 mosquitoes/line were collected and processed for blood feeding experiments.

Virus transmission

To determine whether *Wolbachia*-infected mosquitoes were capable of transmitting infectious virus, 15 blood-fed mosquitoes per line were collected at 14 days post blood feed (donor mosquitoes). The proboscis from each donor was inserted into a 10 μL pipette tip containing 10 μL 1:1 FBS:30% sucrose [62]. Legs and wings were removed to encourage the mosquitoes to spit. Pipette tips were collected 1 hour later and the virus solution ejected onto parafilm. The solution was drawn up into a pulled-glass capillary attached to a handheld microinjector (Nanoject III, Drummond Scientific) and 600 nL was injected into 6 seven-day old recipient *wMel.Tet* mosquitoes. Replicate recipient mosquitoes were stored in a single container for 7-days post injection. RNA was extracted from the whole bodies of all surviving mosquitoes, and qRT-PCR was performed as described above.

Wolbachia density and distribution

Relative *Wolbachia* density in *wMel*, *wAlbB* and *wPip* was determined in whole or dissected tissues from female mosquitoes at 6–7-days post emergence, using qPCR with primers to amplify a fragment of the conserved *16S rRNA* gene (forward primer: 5'-GAGTGAAGAAGG CCTTTGGG-3', reverse primer: 5'-CACGGAGTTAGCCAGGACTTC-3', probe 5' LC640-CTGTGAGTACCGTCATTATCTTCCTCACT-IowaBlackRQ-3') and the reference *Ae. aegypti rps17* gene (forward primer: 5'-TCCGTGGT ATCTCCATCAAGCT-3', reverse primer: 5'-CACTTCCGGCACGTAGTTGTC-3', probe 5' FAM- CAGGAGGAGGAACGTGA GCGCAG-BHQ1-3') [32]. *Wolbachia* densities were quantified relative to *RPS17* using the delta CT method as previously ($2^{\text{CT}}(\text{reference})/2^{\text{CT}}(\text{target})$).

Salivary gland dissections and fluorescence in-situ hybridization (FISH) staining

Female mosquitoes were collected 6-days post emergence, knocked down at -20°C for 2 minutes, then kept in a petri dish on ice until dissection. Individuals were dissected on a microscope slide in a drop of PBS. Briefly, the head of the mosquito was sliced off using a dissection

needle, and the salivary glands popped out by gently squeezing the thorax with needle-tipped forceps. Salivary glands were gently transferred to a small droplet of PBS on poly-lysine-coated slides. Tissues were fixed in cold 4% paraformaldehyde in PBS for 15 minutes, rinsed 3 times in PBS, then permeabilised in 100% ethanol for 5 minutes and air dried. Slides were incubated in hybridization buffer containing fluorescently labelled 16S *rRNA* probes (cross-reactive with all three *Wolbachia* strains) [11] overnight at 37°C in a humidified chamber. Slides were washed in SSC buffers + 10 mM DTT, stained with DAPI, and mounted as described by Moreira *et al.*, 2009 [11].

Confocal microscopy

Slides were imaged using a Nikon C1 Upright confocal microscope at 20X magnification (under oil) as 3-dimensional z-stacks with a step-size of 3 microns. Images were acquired with NIS-Elements software. Maximum Intensity Projection images and scale bars were generated in Fiji software (Version 1.52; National Institutes of Health). Note that the image of wPip salivary glands was produced by stitching together two images taken from the same sample, as the lobes spread too wide to image under a single field of view [63].

Quantitative RT-PCR for immune gene targets

RNA was extracted from 6-day old female mosquitoes (24 per line including Rockefeller, wMel, wAlbB, wPip) using the RNeasy 96 QIAcube HT kit (Qiagen). Samples were DNaseI treated and cDNA was generated from 8 µL of purified RNA/individual (~500 ng of RNA) using SuperScript III First-Strand Synthesis System (ThermoFisher). cDNA was diluted 2-fold with RNase-free water then expression levels of selected immune genes was determined by amplifying 1 µL of cDNA with primers for *cecropin D* (AAEL000598; forward 5'-GCTAGGTCAAACCGAAGCAG, reverse 5'-TCCTACAACAACCGGGAGAG) [24], *cecropin E* (AAEL000611; forward 5'-TTGCACTCGTTCTGCTCATC, reverse 5'-ACACGTTTTCCGACTCCTTC) [24], *defensin C* (AAEL003832-RA; forward 5'-GCTGAGTGGGTTCGGTGTAG, reverse 5'-CGCGTTACAATAGCCTCCTC) [22], *C-type lectin* (AAEL005641; forward 5'-GTCTCCGGGTGCAATACACT, reverse 5'-CCCTATCGTTCCACTTCCAA) [24] or *Transferrin* (AAEL0015458; forward 5'-TCAGGATCTGATGGCCAAAC, reverse 5'-GCCTTGACCTTCTCCAGACA) [24]. Expression levels were normalized to the *Ae. aegypti* house-keeping gene *RPS17* (forward 5'-TCCGTGGTATCTCCATCAAGCT, reverse 5'-CACTTCCGGCACGTAGTTGTC) using the delta CT method ($2^{\text{CT}}(\text{reference})/2^{\text{CT}}(\text{target})$).

Ethics statement

Blood feeding by volunteers (Monash University human ethics permit no CF11/0766-2011000387) for this study was approved by the Monash University Human Research Ethics Committee (MUHREC). All adult volunteers provided informed written consent; no child participants were involved in the study.

Supporting information

S1 Fig. wPip does not restrict DENV dissemination in *Ae. aegypti* following an infectious blood meal. Seven-day old female mosquitoes were fed a blood meal containing DENV-3 (2.09×10^7 TCID₅₀/ml rep. 1 and 3.39×10^6 TCID₅₀/ml rep. 2) and incubated for 14 days. DENV genome copies were determined by qRT-PCR for each head as a measure of viral dissemination. Data are the mean viral genome copies per mosquito head ± SEM, with individual data points overlaid, and were generated from 2 independent experiments (rep. 1 and rep. 2).

Statistical analyses were performed using a Mann-Whitney test where * $p < 0.05$, *** $p < 0.001$, **** $p < 0.0001$. Red line indicates LOD₉₅ of the qRT-PCR reaction. Zero values have been plotted as 10^0 (1) to allow visualization on the log₁₀ scale. Numbers in parentheses above the bars indicates the number of mosquito heads scored positive for DENV per total engorged mosquitoes. Fisher's exact test indicates significantly more mosquitoes show disseminated virus in the wMel.Tet cohort compared to the wMel cohort ($p < 0.00001$ rep. 1 and rep. 2), but no significant difference in the number of mosquitoes showing disseminated virus between wPip and wPip.Tet cohorts ($p > 0.05$ rep. 1 and rep. 2). (TIF)

S2 Fig. Differences in mosquito host genetics do not underlie wPip's lack of antiviral activity. DENV-2 (isolated from a patient in Vietnam in 2010) [37] was injected into the thorax of 7-day old female mosquitoes at 2.4×10^5 TCID₅₀/ml. RNA was extracted from whole mosquito bodies 7-days post infection and virus replication was quantified by qRT-PCR. Data are the mean number of DENV genome copies per mosquito \pm SEM with individual data points overlaid. Asterisks indicate significance compared to Rockefeller (no *Wolbachia* control) (Kruskal-Wallis test with Dunn's correction; **** $p < 0.0001$). (TIF)

Acknowledgments

We wish to thank Etienne C. Pacidônio, Daniela S. Gonçalves, Kimberley Dainty, Ritzel Gimeno and Elvina Lee for technical assistance. We thank Professor Roy Hall (University of Queensland) for provision of the 4G2 antibody, and Professor Jason Mackenzie (University of Melbourne) for gifting the Kunjin virus stock. The authors acknowledge Monash Micro Imaging, Monash University, for the provision of instrumentation, training and technical support. The following reagent was obtained through BEI Resources, NIAID, NIH: *Aedes aegypti*, Strain ROCK, MRA-734, contributed by David W. Severson.

Author Contributions

Conceptualization: Johanna E. Fraser, Heather A. Flores.

Data curation: Johanna E. Fraser, Tanya B. O'Donnell, Johanna M. Duyvestyn, Heather A. Flores.

Formal analysis: Johanna E. Fraser, Tanya B. O'Donnell.

Funding acquisition: Johanna E. Fraser, Scott L. O'Neill.

Methodology: Johanna E. Fraser, Tanya B. O'Donnell, Heather A. Flores.

Supervision: Johanna E. Fraser, Cameron P. Simmons, Heather A. Flores.

Writing – original draft: Johanna E. Fraser.

Writing – review & editing: Johanna E. Fraser, Scott L. O'Neill, Cameron P. Simmons, Heather A. Flores.

References

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. *Nature*. 2013; 496(7446):504–7. <https://doi.org/10.1038/nature12060> PMID: 23563266

2. Mayer SV, Tesh RB, Vasilakis N. The emergence of arthropod-borne viral diseases: A global prospective on dengue, chikungunya and zika fevers. *Acta Trop.* 2017; 166:155–63. Epub 2016/11/24. <https://doi.org/10.1016/j.actatropica.2016.11.020> PMID: 27876643
3. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasonondh T, Chua MN, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. *Lancet.* 2014; 384(9951):1358–65. [https://doi.org/10.1016/S0140-6736\(14\)61060-6](https://doi.org/10.1016/S0140-6736(14)61060-6) PMID: 25018116.
4. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasonondh T, Dietze R, et al. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. *N Engl J Med.* 2015; 373(13):1195–206. <https://doi.org/10.1056/NEJMoa1506223> PMID: 26214039.
5. Pang EL, Loh HS. Towards development of a universal dengue vaccine—How close are we? *Asian Pac J Trop Med.* 2017; 10(3):220–8. <https://doi.org/10.1016/j.apjtm.2017.03.003> PMID: 28442105.
6. Simmons CP. A Candidate Dengue Vaccine Walks a Tightrope. *N Engl J Med.* 2015; 373(13):1263–4. <https://doi.org/10.1056/NEJMe1509442> PMID: 26214040.
7. Zug R, Hammerstein P. Still a host of hosts for Wolbachia: analysis of recent data suggests that 40% of terrestrial arthropod species are infected. *PLoS One.* 2012; 7(6):e38544. <https://doi.org/10.1371/journal.pone.0038544> PMID: 22685581
8. Hedges LM, Johnson KN. Induction of host defence responses by *Drosophila C* virus. *J Gen Virol.* 2008; 89(Pt 6):1497–501. <https://doi.org/10.1099/vir.0.83684-0> PMID: 18474566.
9. Teixeira L, Ferreira A, Ashburner M. The bacterial symbiont Wolbachia induces resistance to RNA viral infections in *Drosophila melanogaster*. *PLoS Biol.* 2008; 6(12):e2. <https://doi.org/10.1371/journal.pbio.1000002> PMID: 19222304
10. Chrostek E, Marialva MS, Esteves SS, Weinert LA, Martinez J, Jiggins FM, et al. Wolbachia variants induce differential protection to viruses in *Drosophila melanogaster*: a phenotypic and phylogenomic analysis. *PLoS Genet.* 2013; 9(12):e1003896. <https://doi.org/10.1371/journal.pgen.1003896> PMID: 24348259
11. Moreira LA, Iturbe-Ormaetxe I, Jeffery JA, Lu G, Pyke AT, Hedges LM, et al. A Wolbachia symbiont in *Aedes aegypti* limits infection with dengue, Chikungunya, and Plasmodium. *Cell.* 2009; 139(7):1268–78. <https://doi.org/10.1016/j.cell.2009.11.042> PMID: 20064373.
12. Aliota MT, Walker EC, Uribe Yepes A, Velez ID, Christensen BM, Osorio JE. The wMel Strain of Wolbachia Reduces Transmission of Chikungunya Virus in *Aedes aegypti*. *PLoS Negl Trop Dis.* 2016; 10(4):e0004677. <https://doi.org/10.1371/journal.pntd.0004677> PMID: 27124663
13. Bian G, Xu Y, Lu P, Xie Y, Xi Z. The endosymbiotic bacterium Wolbachia induces resistance to dengue virus in *Aedes aegypti*. *PLoS Pathog.* 2010; 6(4):e1000833. <https://doi.org/10.1371/journal.ppat.1000833> PMID: 20368968
14. Dutra HL, Rocha MN, Dias FB, Mansur SB, Caragata EP, Moreira LA. Wolbachia Blocks Currently Circulating Zika Virus Isolates in Brazilian *Aedes aegypti* Mosquitoes. *Cell Host Microbe.* 2016; 19(6):771–4. <https://doi.org/10.1016/j.chom.2016.04.021> PMID: 27156023
15. Walker T, Johnson PH, Moreira LA, Iturbe-Ormaetxe I, Frentiu FD, McMeniman CJ, et al. The wMel Wolbachia strain blocks dengue and invades caged *Aedes aegypti* populations. *Nature.* 2011; 476(7361):450–3. <https://doi.org/10.1038/nature10355> PMID: 21866159.
16. Nazni WA, Hoffmann AA, NoorAfizah A, Cheong YL, Mancini MV, Golding N, et al. Establishment of Wolbachia Strain wAlbB in Malaysian Populations of *Aedes aegypti* for Dengue Control. *Current Biology.* 2019. <https://doi.org/10.1016/j.cub.2019.11.007>.
17. O'Neill SL, Ryan PA, Turley AP, Wilson G, Retzki K, Iturbe-Ormaetxe I, et al. Scaled deployment of Wolbachia to protect the community from dengue and other *Aedes* transmitted arboviruses. *Gates Open Res.* 2018; 2:36. <https://doi.org/10.12688/gatesopenres.12844.3> PMID: 30596205
18. Ryan PA, Turley AP, Wilson G, Hurst TP, Retzki K, Brown-Kenyon J, et al. Establishment of wMel Wolbachia in *Aedes aegypti* mosquitoes and reduction of local dengue transmission in Cairns and surrounding locations in northern Queensland, Australia. *Gates Open Res.* 2019; 3:1547. Epub 2019/11/02. <https://doi.org/10.12688/gatesopenres.13061.2> PMID: 31667465
19. Caragata EP, Rances E, Hedges LM, Gofton AW, Johnson KN, O'Neill SL, et al. Dietary cholesterol modulates pathogen blocking by Wolbachia. *PLoS Pathog.* 2013; 9(6):e1003459. <https://doi.org/10.1371/journal.ppat.1003459> PMID: 23825950
20. Cho K-O, Kim G-W, Lee O-K. Wolbachia Bacteria Reside in Host Golgi-Related Vesicles Whose Position Is Regulated by Polarity Proteins. *PLOS ONE.* 2011; 6(7):e22703. <https://doi.org/10.1371/journal.pone.0022703> PMID: 21829485
21. White PM, Serbus LR, Debec A, Codina A, Bray W, Guichet A, et al. Reliance of Wolbachia on High Rates of Host Proteolysis Revealed by a Genome-Wide RNAi Screen of *Drosophila* Cells. *Genetics.* 2017; 205(4):1473. <https://doi.org/10.1534/genetics.116.198903> PMID: 28159754

22. Rances E, Ye YH, Woolfit M, McGraw EA, O'Neill SL. The relative importance of innate immune priming in Wolbachia-mediated dengue interference. *PLoS Pathog.* 2012; 8(2):e1002548. <https://doi.org/10.1371/journal.ppat.1002548> PMID: 22383881
23. Pan X, Zhou G, Wu J, Bian G, Lu P, Raikhel AS, et al. Wolbachia induces reactive oxygen species (ROS)-dependent activation of the Toll pathway to control dengue virus in the mosquito *Aedes aegypti*. *Proc Natl Acad Sci U S A.* 2012; 109(1):E23–31. <https://doi.org/10.1073/pnas.1116932108> PMID: 22123956
24. Kambris Z, Cook PE, Phuc HK, Sinkins SP. Immune activation by life-shortening Wolbachia and reduced filarial competence in mosquitoes. *Science.* 2009; 326(5949):134–6. Epub 2009/10/03. <https://doi.org/10.1126/science.1177531> PMID: 19797660
25. Geoghegan V, Stainton K, Rainey SM, Ant TH, Dowle AA, Larson T, et al. Perturbed cholesterol and vesicular trafficking associated with dengue blocking in Wolbachia-infected *Aedes aegypti* cells. *Nature Communications.* 2017; 8(1):526. <https://doi.org/10.1038/s41467-017-00610-8> PMID: 28904344
26. Caragata EP, Rancès E, O'Neill SL, McGraw EA. Competition for Amino Acids Between Wolbachia and the Mosquito Host, *Aedes aegypti*. *Microbial Ecology.* 2014; 67(1):205–18. <https://doi.org/10.1007/s00248-013-0339-4> PMID: 24337107
27. Caragata EP, Rancès E, Hedges LM, Gofton AW, Johnson KN, O'Neill SL, et al. Dietary cholesterol modulates pathogen blocking by Wolbachia. *PLoS pathogens.* 2013; 9(6):e1003459–e. Epub 2013/06/27. <https://doi.org/10.1371/journal.ppat.1003459> PMID: 23825950.
28. Haqshenas G, Terradas G, Paradkar PN, Duchemin J-B, McGraw EA, Doerig C. A Role for the Insulin Receptor in the Suppression of Dengue Virus and Zika Virus in Wolbachia-Infected Mosquito Cells. *Cell Reports.* 2019; 26(3):529–35.e3. <https://doi.org/10.1016/j.celrep.2018.12.068> PMID: 30650347
29. Ford SA, Allen SL, Ohm JR, Sigle LT, Sebastian A, Albert I, et al. Selection on *Aedes aegypti* alters Wolbachia-mediated dengue virus blocking and fitness. *Nature Microbiology.* 2019; 4(11):1832–9. <https://doi.org/10.1038/s41564-019-0533-3> PMID: 31451771
30. Terradas G, McGraw EA. Wolbachia-mediated virus blocking in the mosquito vector *Aedes aegypti*. *Curr Opin Insect Sci.* 2017; 22:37–44. Epub 2017/08/15. <https://doi.org/10.1016/j.cois.2017.05.005> PMID: 28805637.
31. Lindsey ARI, Bhattacharya T, Newton ILG, Hardy RW. Conflict in the Intracellular Lives of Endosymbionts and Viruses: A Mechanistic Look at Wolbachia-Mediated Pathogen-blocking. *Viruses.* 2018; 10(4). Epub 2018/03/22. <https://doi.org/10.3390/v10040141> PMID: 29561780
32. Fraser JE, De Bruyne JT, Iturbe-Ormaetxe I, Stepnell J, Burns RL, Flores HA, et al. Novel Wolbachia-transinfected *Aedes aegypti* mosquitoes possess diverse fitness and vector competence phenotypes. *PLoS Pathog.* 2017; 13(12):e1006751. <https://doi.org/10.1371/journal.ppat.1006751> PMID: 29216317.
33. McMeniman CJ, Lane RV, Cass BN, Fong AW, Sidhu M, Wang YF, et al. Stable introduction of a life-shortening Wolbachia infection into the mosquito *Aedes aegypti*. *Science.* 2009; 323(5910):141–4. <https://doi.org/10.1126/science.1165326> PMID: 19119237.
34. Ant TH, Herd CS, Geoghegan V, Hoffmann AA, Sinkins SP. The Wolbachia strain wAu provides highly efficient virus transmission blocking in *Aedes aegypti*. *PLoS Pathog.* 2018; 14(1):e1006815. Epub 2018/01/26. <https://doi.org/10.1371/journal.ppat.1006815> PMID: 29370307
35. Chouin-Carneiro T, Ant TH, Herd C, Louis F, Failloux AB, Sinkins SP. Wolbachia strain wAlbA blocks Zika virus transmission in *Aedes aegypti*. *Med Vet Entomol.* 2019. Epub 2019/05/24. <https://doi.org/10.1111/mve.12384> PMID: 31120156.
36. Xi Z, Khoo CC, Dobson SL. Wolbachia establishment and invasion in an *Aedes aegypti* laboratory population. *Science.* 2005; 310(5746):326–8. <https://doi.org/10.1126/science.1117607> PMID: 16224027.
37. Flores HA, Taneja de Bruyne J, O'Donnell TB, Tuyet Nhu V, Thi Giang N, Thi Xuan Trang H, et al. Multiple Wolbachia strains provide comparative levels of protection against dengue virus infection in *Aedes aegypti*. *PLOS Pathogens.* 2020; 16(4):e1008433. <https://doi.org/10.1371/journal.ppat.1008433> PMID: 32282862
38. Glaser RL, Meola MA. The native Wolbachia endosymbionts of *Drosophila melanogaster* and *Culex quinquefasciatus* increase host resistance to West Nile virus infection. *PLoS One.* 2010; 5(8):e11977. <https://doi.org/10.1371/journal.pone.0011977> PMID: 20700535
39. Frentiu FD, Robinson J, Young PR, McGraw EA, O'Neill SL. Wolbachia-mediated resistance to dengue virus infection and death at the cellular level. *PLoS One.* 2010; 5(10):e13398. <https://doi.org/10.1371/journal.pone.0013398> PMID: 20976219
40. Lu P, Bian G, Pan X, Xi Z. Wolbachia induces density-dependent inhibition to dengue virus in mosquito cells. *PLoS Negl Trop Dis.* 2012; 6(7):e1754. <https://doi.org/10.1371/journal.pntd.0001754> PMID: 22848774

41. Osborne SE, Iturbe-Ormaetxe I, Brownlie JC, O'Neill SL, Johnson KN. Antiviral protection and the importance of Wolbachia density and tissue tropism in *Drosophila simulans*. *Appl Environ Microbiol*. 2012; 78(19):6922–9. <https://doi.org/10.1128/AEM.01727-12> PMID: 22843518
42. Joubert DA, O'Neill SL. Comparison of Stable and Transient Wolbachia Infection Models in *Aedes aegypti* to Block Dengue and West Nile Viruses. *PLoS Negl Trop Dis*. 2017; 11(1):e0005275. <https://doi.org/10.1371/journal.pntd.0005275> PMID: 28052065.
43. Xi Z, Ramirez JL, Dimopoulos G. The *Aedes aegypti* Toll Pathway Controls Dengue Virus Infection. *PLoS Pathogens*. 2008; 4(7):e1000098. <https://doi.org/10.1371/journal.ppat.1000098> PMID: 18604274
44. Martinez J, Longdon B, Bauer S, Chan YS, Miller WJ, Bourtzis K, et al. Symbionts commonly provide broad spectrum resistance to viruses in insects: a comparative analysis of Wolbachia strains. *PLoS Pathog*. 2014; 10(9):e1004369. <https://doi.org/10.1371/journal.ppat.1004369> PMID: 25233341
45. Amuzu HE, McGraw EA. Wolbachia-Based Dengue Virus Inhibition Is Not Tissue-Specific in *Aedes aegypti*. *PLoS Negl Trop Dis*. 2016; 10(11):e0005145. Epub 2016/11/18. <https://doi.org/10.1371/journal.pntd.0005145> PMID: 27855218
46. Salazar MI, Richardson JH, Sánchez-Vargas I, Olson KE, Beaty BJ. Dengue virus type 2: replication and tropisms in orally infected *Aedes aegypti* mosquitoes. *BMC Microbiology*. 2007; 7(1):9. <https://doi.org/10.1186/1471-2180-7-9> PMID: 17263893
47. Hugo LE, Stassen L, La J, Gosden E, Ekwudu Om, Winterford C, et al. Vector competence of Australian *Aedes aegypti* and *Aedes albopictus* for an epidemic strain of Zika virus. *PLoS Neglected Tropical Diseases*. 2019; 13(4):e0007281. <https://doi.org/10.1371/journal.pntd.0007281> PMID: 30946747
48. Moretti R, Yen P-S, Houé V, Lampazzi E, Desiderio A, Failloux A-B, et al. Combining Wolbachia-induced sterility and virus protection to fight *Aedes albopictus*-borne viruses. *PLoS Neglected Tropical Diseases*. 2018; 12(7):e0006626. <https://doi.org/10.1371/journal.pntd.0006626> PMID: 30020933
49. Zhang D, Zheng X, Xi Z, Bourtzis K, Gilles JR. Combining the sterile insect technique with the incompatible insect technique: I-impact of wolbachia infection on the fitness of triple- and double-infected strains of *Aedes albopictus*. *PLoS One*. 2015; 10(4):e0121126. <https://doi.org/10.1371/journal.pone.0121126> PMID: 25849812
50. Atyame CM, Delsuc F, Pasteur N, Weill M, Duron O. Diversification of Wolbachia Endosymbiont in the *Culex pipiens* Mosquito. *Molecular Biology and Evolution*. 2011; 28(10):2761–72. <https://doi.org/10.1093/molbev/msr083> PMID: 21515811
51. Osborne SE, Leong YS, O'Neill SL, Johnson KN. Variation in antiviral protection mediated by different Wolbachia strains in *Drosophila simulans*. *PLoS Pathog*. 2009; 5(11):e1000656. <https://doi.org/10.1371/journal.ppat.1000656> PMID: 19911047
52. Grobler Y, Yun CY, Kahler DJ, Bergman CM, Lee H, Oliver B, et al. Whole genome screen reveals a novel relationship between Wolbachia levels and *Drosophila* host translation. *PLoS Pathog*. 2018; 14(11):e1007445. <https://doi.org/10.1371/journal.ppat.1007445> PMID: 30422992
53. Zheng Y, Wang J-L, Liu C, Wang C-P, Walker T, Wang Y-F. Differentially expressed profiles in the larval testes of Wolbachia infected and uninfected *Drosophila*. *BMC Genomics*. 2011; 12(1):595. <https://doi.org/10.1186/1471-2164-12-595> PMID: 22145623
54. LePage DP, Metcalf JA, Bordenstein SR, On J, Perlmutter JI, Shropshire JD, et al. Prophage WO genes recapitulate and enhance Wolbachia-induced cytoplasmic incompatibility. *Nature*. 2017; 543(7644):243–7. Epub 2017/02/27. <https://doi.org/10.1038/nature21391> PMID: 28241146.
55. Joubert DA, Walker T, Carrington LB, De Bruyne JT, Kien DH, Hoang Nle T, et al. Establishment of a Wolbachia Superinfection in *Aedes aegypti* Mosquitoes as a Potential Approach for Future Resistance Management. *PLoS Pathog*. 2016; 12(2):e1005434. <https://doi.org/10.1371/journal.ppat.1005434> PMID: 26891349.
56. Ye YH, Carrasco AM, Frentiu FD, Chenoweth SF, Beebe NW, van den Hurk AF, et al. Wolbachia Reduces the Transmission Potential of Dengue-Infected *Aedes aegypti*. *PLoS Neglected Tropical Diseases*. 2015; 9(6):e0003894. <https://doi.org/10.1371/journal.pntd.0003894> PMID: 26115104
57. Kuno G. Early History of Laboratory Breeding of *Aedes aegypti* (Diptera: Culicidae) Focusing on the Origins and Use of Selected Strains. *Journal of Medical Entomology*. 2014; 47(6):957–71. <https://doi.org/10.1603/ME10152> PMID: 21175042
58. O'Brien CA, Hobson-Peters J, Yam AW, Colmant AM, McLean BJ, Prow NA, et al. Viral RNA intermediates as targets for detection and discovery of novel and emerging mosquito-borne viruses. *PLoS Negl Trop Dis*. 2015; 9(3):e0003629. <https://doi.org/10.1371/journal.pntd.0003629> PMID: 25799391
59. Gentry MK, Henchal EA, McCown JM, Brandt WE, Dalrymple JM. Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies. *Am J Trop Med Hyg*. 1982; 31(3 Pt 1):548–55. <https://doi.org/10.4269/ajtmh.1982.31.548> PMID: 6177259.

60. Ritchie SA, Pyke AT, Hall-Mendelin S, Day A, Mores CN, Christofferson RC, et al. An explosive epidemic of DENV-3 in Cairns, Australia. *PLoS one*. 2013; 8(7):e68137. <https://doi.org/10.1371/journal.pone.0068137> PMID: 23874522.
61. Pyke AT, Smith IL, van den Hurk AF, Northill JA, Chuan TF, Westacott AJ, et al. Detection of Australasian Flavivirus encephalitic viruses using rapid fluorogenic TaqMan RT-PCR assays. *J Virol Methods*. 2004; 117(2):161–7. <https://doi.org/10.1016/j.jviromet.2004.01.007> PMID: 15041213.
62. Nguyen NM, Thi Hue Kien D, Tuan TV, Quyen NTH, Tran CNB, Vo Thi L, et al. Host and viral features of human dengue cases shape the population of infected and infectious *Aedes aegypti* mosquitoes. *Proceedings of the National Academy of Sciences*. 2013; 110(22):9072. <https://doi.org/10.1073/pnas.1303395110> PMID: 23674683
63. Preibisch S, Saalfeld S, Tomancak P. Globally optimal stitching of tiled 3D microscopic image acquisitions. *Bioinformatics*. 2009; 25(11):1463–5. <https://doi.org/10.1093/bioinformatics/btp184> PMID: 19346324